Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in antitumor anthracyclines

F Arcamone1, F Animati, G Capranico

  • 1Menarini Ricerche, Rome, Italy.

Pharmacology & Therapeutics
|April 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Studies on the chemistry of a glucoside a antibiotic from a Streptomyces sp.

Antibiotics & chemotherapy (Northfield, Ill.)·2014
Same author

Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.

The Journal of pharmacology and experimental therapeutics·2013
Same author

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Biochemical pharmacology·2013
Same author

Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothecin-based treatment.

Current medicinal chemistry·2010
Same author

ABC transporters as potential targets for modulation of drug resistance.

Mini reviews in medicinal chemistry·2009
Same author

Small molecules targeting p53 to improve antitumor therapy.

Mini reviews in medicinal chemistry·2008
Same journal

Protein acetylation modification in tissue fibrosis: Opportunities and challenges.

Pharmacology & therapeutics·2026
Same journal

Nipocalimab and other FcRn blockers in neuromuscular disorders.

Pharmacology & therapeutics·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
See all related articles

Doxorubicin analogs like epirubicin and idarubicin have advanced cancer treatment. New synthetic derivatives, including disaccharides, show promise as third-generation anthracycline anticancer agents in clinical trials.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Doxorubicin, a key anticancer agent since the 1970s, has spurred analog development.
  • Epirubicin and idarubicin represent improved tolerability and potency, respectively.

Purpose of the Study:

  • To synthesize novel anthracycline derivatives based on molecular insights.
  • To evaluate the pharmacological activity of new synthetic compounds, particularly disaccharides.

Main Methods:

  • Analogue synthesis programs.
  • Target-oriented pharmacological experiments.
  • Structure-activity relationship studies focusing on sugar moiety orientation.

Main Results:

  • Synthesis of 8- and 10-fluoro anthracycline derivatives.

Related Experiment Videos

  • Development of disaccharide derivatives with activity dependent on daunosamine orientation.
  • Identification of a promising third-generation anthracycline candidate undergoing clinical trials.

    • Conclusions:

    • Novel anthracycline derivatives offer potential for improved anticancer therapy.
    • Structural modifications, especially sugar moiety configuration, significantly impact biological activity.
    • Ongoing clinical trials for a new disaccharide derivative indicate its therapeutic potential.